Viewing stories from August, 2016
Highlights of FY2016 Presentation: FNN Interview
Starpharma advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network.
Annual Report and full year financial results
Starpharma released its annual report and financial results for the year ended 30 June 2016.
Financial Results
- Net cash burn (cash outflows before new capital) $17.5M
- Cash position at end of the year $46.0M
- Net proceeds of $32.6M from equity placement and share purchase plan
- Total revenue and other income $4.6M including the first US$2M DEP™ milestone from AstraZeneca
- Reported loss $22.7M
- Receipt of $3.4M R&D tax incentive
The Australian: Starpharma perks up on China condom deal
The Australian’s David Rogers reports that Starpharma has signed “an exclusive license and supply agreement with Shenyang SKY and Land Latex Co for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market”.